Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry
Tsimafeyeu I. Shatkovskaya O. Krasny S. Nurgaliev N. Varlamov I. Petkau V. Safina S. Zukov R. Mazhbich M. Statsenko G. Varlamov S. Novikova O. Zaitsev I. Moiseyev P. Rolevich A. Evmenenko A. Popova I. Kaidarova D. Vladimirova L.
June 2021John Wiley and Sons Inc
Cancer Reports
2021#4Issue 3
Background: Real-world data describing outcomes of treatment among metastatic renal cell carcinoma (mRCC) patients are limited and heterogeneous. Aim: RENSUR3 registry study assessed real-world data on the use of therapies in mRCC and overall survival (OS) in Russia, Kazakhstan, and Belarus. Methods: Patients were included in the retrospective multicenter registry study. To be eligible, patients were required to have mRCC diagnosed from January 2015 to January 2016. Anonymized data were collected through an online registry. The outcomes of interest were patient characteristics, treatment patterns, and OS. Results: 1094 mRCC patients were identified. Mean age was 62.3 (SD, 11.2) years. Four hundred and forty-four (41%) patients were 65 years and older. Primary tumor has not been removed in 503 (46%) patients. Subtype of RCC based on WHO classification (clear-cell or other) has been reported in 402 (37%) patients. In total, 595 (54.4%) patients received systemic therapy for metastatic disease. 58% of elderly patients (≥65) were not treated compared to 37% of younger patients. Cytokines and targeted therapy were used in 298 (50.1%) and 297 (49.9%) of 595 treated patients, respectively. Median OS was 11.9 months (95% CI 10.9-12.9). The 1- and 3-year OS rates were 49.6% and 19.3%. Conclusions: Half of patients received no systemic therapy or had only cytokines for mRCC in Russia, Kazakhstan, and Belarus, which doubtless negatively affected OS in this population. Novel therapies should be considered as life prolonging and a priority.
metastatic renal cell carcinoma , overall survival , registry , treatment patterns
Text of the article Перейти на текст статьи
Kidney Cancer Research Bureau, Moscow, Russian Federation
Institute of Oncology, Hadassah Medical Moscow, Moscow, Russian Federation
Department of Strategic Development and International Relations, Kazakh Institute of Oncology and Radiology, Almaty, Kazakhstan
N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Republic of Belarus, Belarus
Department of Urology, Kazakh Institute of Oncology and Radiology, Almaty, Kazakhstan
Department of Urology, Altai Regional Cancer Center, Barnaul, Russian Federation
Out-Patient Department, Sverdlovsk Regional Oncological Dispensary, Ekaterinburg, Russian Federation
Chemotherapy Department, Republican Clinical Oncology Dispensary, Kazan, Russian Federation
V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russian Federation
Department of Urology, Omsk Regional Cancer Center, Omsk, Russian Federation
Omsk Regional Cancer Center, Omsk, Russian Federation
Chemotherapy Department, Khabarovsk Regional Cancer Center, Khabarovsk, Russian Federation
Department of Urology, Astrakhan Regional Cancer Center, Astrakhan, Russian Federation
Organization of Anticancer Control, N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Republic of Belarus, Belarus
Laboratory of Oncourological Pathologies, N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Republic of Belarus, Belarus
Department of the Organization of Anticancer Control, N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Republic of Belarus, Belarus
Department of Medical Oncology, National Medical Research Centre for Oncology, Rostov-on-Done, Russian Federation
Kazakh Institute of Oncology and Radiology, Almaty, Kazakhstan
Kidney Cancer Research Bureau
Institute of Oncology
Department of Strategic Development and International Relations
N.N. Alexandrov National Cancer Centre of Belarus
Department of Urology
Department of Urology
Out-Patient Department
Chemotherapy Department
V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University
Department of Urology
Omsk Regional Cancer Center
Chemotherapy Department
Department of Urology
Organization of Anticancer Control
Laboratory of Oncourological Pathologies
Department of the Organization of Anticancer Control
Department of Medical Oncology
Kazakh Institute of Oncology and Radiology
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026